Abstract 90P
Background
Neutrophils (Nph) can play both protumor (N2) and antitumor (N1) roles at different stages of carcinogenesis. The tumor microenvironment promotes Nph polarization and enhances pro-angiogenic properties, contributing to changes in serum endothelial growth factor-A (VEGF-A) levels (Amorim C. et al., 2022).The aim of the study was to evaluate the ability of circulating neutrophils to produce VEGF-A during the progression of kidney cancer (KC).
Methods
The object of the study was the blood Nph of patients with KC before treatment, clear cell type I stage (T1N0M0G1, n=28, 60 years), II stage (T2N0M0G2, n=15, 61 years) and III stage (T3N0M0G2, n=15, 63 years) and the control group (n=15, 54 years). RNA was isolated from the peripheral blood Nph fraction on SileksMagNA magnetic particles (Sileks, Russia). The reverse transcription reaction was carried out and the expression of the VEGF-A gene was determined by quantitative PCR using primers (Evrogen, Russia). The level of VEGF-A in serum (pg/ml) was determined by ELISA (Vector-Best-Volga, Russia). The results are presented as Me (Q1-Q3). Statistical processing was performed in Statistica 13 (Mann–Whitney U test, Spearman correlation coefficient (p<0.05)). The study was approved by the Ethics Committee of IME&PK UlSU (protocol No. 1 of 01/15/2020).
Results
We found an increase in the serum level of VEGF-A at all stages of KC (stage I: 227.34 (227.34-399.49), p=0.002; stage II: 337.52 (329.33-692.18), p = 0.0005; III stage: 372.99 (282.99-545.82), p=0.001) relative to the control group (136.34 (91.01-168.95)). This may be due to the development of the angiogenic process during the progression of KC. The absolute amount of Nph decreased depending on the stage of KC: 4.6x109/l at stage I, 3.95x109/l - at stage III, 3.75x109/l - at stage IV. Expression of the VEGF-A gene by circulating Nph did not change at different stages of KC. However, at stage III KC, a correlation was found between VEGF-A gene expression in Nph and the level of this factor in serum (r=0.321, p=0.05).
Conclusions
Our results suggest that circulating Nph in KC has a high potential for VEGF-A production. At the same time, in stage III of KC, the serum level of VEGF-A is associated with an increased release of intracellular VEGF-A from Nph.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract